Provided by Tiger Trade Technology Pte. Ltd.

Adial Pharmaceuticals

5.79
+0.19003.39%
Volume:65.47K
Turnover:368.15K
Market Cap:15.20M
PE:-0.33
High:5.98
Open:5.57
Low:5.30
Close:5.60
52wk High:10.75
52wk Low:1.31
Shares:2.63M
Float Shares:2.13M
Volume Ratio:0.99
T/O Rate:3.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.7100
EPS(LYR):-11.9306
ROE:-2011.64%
ROA:-40.02%
PB:-0.40
PE(LYR):-0.49

Loading ...

Company Profile

Company Name:
Adial Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
5
Office Location:
4870 Sadler Road,Suite 300,Glen Allen,Virginia,United States
Zip Code:
23060
Fax:
- -
Introduction:
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

Directors

Name
Position
Cary J. Claiborne
Chief Executive Officer and Director and President
Kevin Schuyler
Chairman of the Board and Lead Independent Director
Matthew Davidson
Chief Development Officer and Director
J. Kermit Anderson
Director
Robertson H. Gilliland
Director
Wendy B. Young
Director

Shareholders

Name
Position
Cary J. Claiborne
Chief Executive Officer and Director and President
Vinay Shah
Chief Financial Officer
Matthew Davidson
Chief Development Officer and Director